Journal
Therapeutic Advances in Gastroenterology
Publication Date
6-12-2023
Volume
16
First Page
e17562848231174277
Document Type
Open Access Publication
DOI
10.1177/17562848231174277
Rights and Permissions
Lee C, Louie T, Bancke L, Guthmueller B, Harvey A, Feuerstadt P, Khanna S, Orenstein R, Dubberke ER. Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. Therap Adv Gastroenterol. 2023 Jun 12;16:17562848231174277. doi: 10.1177/17562848231174277. © The Author(s), 2023. Creative Commons License (CC BY-NC 4.0) This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). Request permissions for this article.
Recommended Citation
Lee, Christine; Louie, Thomas; Bancke, Lindy; Guthmueller, Beth; Harvey, Adam; Feuerstadt, Paul; Khanna, Sahil; Orenstein, Robert; and Dubberke, Erik R, "Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: Data from five prospective clinical trials." Therapeutic Advances in Gastroenterology. 16, e17562848231174277 (2023).
https://digitalcommons.wustl.edu/oa_4/2042
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
